TORONTO, Canada (August 21, 2008) – Patheon Inc. (TSX: PTI) will host a conference call with financial analysts on Friday, September 5, 2008 at 10:00 a.m. (EST) to discuss its third quarter 2008 financial results. The third quarter financial results news release will be issued at approximately 7:00 a.m. (EST) on Friday, September 5, 2008.

Interested parties are invited to access the live call, via telephone, in listen-only mode, at (416) 644-3414 (Toronto and International) or toll free at (800) 733-7571 (U.S., including Puerto Rico). Listeners are encouraged to dial in five to 15 minutes in advance to avoid delays. A live audio webcast will also be available via the web at www.patheon.com. (Please note that Windows Media Player or RealPlayer is required.)

A telephone replay of the conference call will be available between Friday, September 5, 2008 and Friday, September 12, 2008 by calling (416) 640-1917 or (877) 289-8525 (toll free) and entering identification number 21280762,  followed by the number key. The webcast will also be archived on www.patheon.com for three months.

ABOUT PATHEON
Patheon Inc. (TSX:PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry.  Patheon prides itself in providing the highest quality products and services to more than 300 of the world’s leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms.  Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.

Patheon’s comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization.  Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon’s Quick to Clinic™ programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.

Patheon’s integrated development and manufacturing network of 11 facilities, and 6 development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.

Caution Concerning Forward-Looking Statements
This news release may contain forward-looking statements which reflect management’s expectations regarding the Company’s future growth of operations, performance (both operational and financial) and business prospects and opportunities.  These statements are made in the context of the risks and uncertainties that are outlined in the Company’s public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.

Contacts: